MannKind Corporation (NASDAQ:MNKD) In the U.S. alone, roughly 1 of 12 people are managing diabetes. China has approximately 100 million diabetic patients as of 2012 statistics. Total global insulin sales have grown an average of $4 billion a year between 2011 and 2012 ($16.8B in 2011 and $20.8B in 2012). However, in 2013, sharp price increases sent the total market up to $35 billion.MannKind Corporation (NASDAQ:MNKD) weekly performance is 13.06%.On last trading day company shares ended up $7.01. Analysts mean target price for the company is $7.57. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 15.85%.
Shares of online retailer Zulily Inc (NASDAQ:ZU) shot up more than 8 percent on Wednesday, rebounding after dropping to a record low earlier in the day following the expiration of its lockup period.Zulily Inc (NASDAQ:ZU) shares advanced/ 9.31% in last trading session and ended the day on $34.99. ZU Gross Margin is 27.30% and its return on assets is -1.10%.Zulily Inc (NASDAQ:ZU) quarterly performance is -11.75%
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago.Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved up 26.94% in last trading session and was closed at $15.74, while trading in range of $12.85 – $15.97. Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date (YTD) performance is -34.99%.
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) reported financial results for the three and six months ended March 31, 2014. Total net revenues for the second quarter fiscal 2014 were $26.9 million, compared with $17.4 million for the comparable quarter in fiscal 2013, representing 55 percent year-over-year growth. Net loss for the fiscal 2014 second quarter was $12.7 million, or $0.08 per share, compared with a net loss of $16.5 million, or $0.12 per share, for the same period in fiscal 2013.Avanir Pharmaceuticals Inc (NASDAQ:AVNR) ended the last trading day at $5.05. Company weekly volatility is calculated as 7.98%and price to cash ratio as 18.39. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) showed a positive weekly performance of 13.74%.
Leave a Reply